Skip to main content

ImmuPharma expects new Lupozor study to begin in H2 2023

--News Direct--

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio after announcing that its partner Avion Pharmaceuticals is to launch an adaptive phase II/III clinical study on Lupuzor, the former’s discovery and putative treatment for systemic lupus erythematosus (SLE). McCarthy reveals the reasons for choosing the particular type of study and explains what else investors can expect from ImmuPharma during 2023.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.